Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HR7Z
|
|||
| Former ID |
DIB013653
|
|||
| Drug Name |
PF-05280014
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Company |
Pfizer
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02187744) A Study Of PF-05280014 Or Trastuzumab Plus Taxotere And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04). U.S. National Institutes of Health. | |||
| REF 2 | Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.